BioRegenx, Inc. (BRGX)
OTCMKTS · Delayed Price · Currency is USD
0.0001
-0.0001 (-50.00%)
At close: Nov 4, 2026
BioRegenx Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1.77 | 1.85 | 2.34 | 3.41 | 2.44 | 3.99 | |
Revenue Growth | -23.43% | -20.75% | -31.40% | 39.97% | -38.88% | -48.79% |
Cost of Revenue | 0.32 | 0.35 | 0.68 | 1.1 | 0.8 | 1.43 |
Gross Profit | 1.45 | 1.5 | 1.66 | 2.31 | 1.64 | 2.56 |
Selling, General & Admin | 1.82 | 2.02 | 6.03 | 5.72 | 3.53 | 5.81 |
Amortization of Goodwill & Intangibles | - | - | 2.18 | - | - | - |
Operating Expenses | 1.82 | 2.02 | 8.21 | 5.72 | 3.53 | 5.81 |
Operating Income | -0.38 | -0.52 | -6.55 | -3.41 | -1.89 | -3.25 |
Interest Expense | -0.3 | -0.3 | -0.29 | -0.19 | -0.34 | -0.45 |
Interest & Investment Income | - | - | - | - | 0 | 0.03 |
EBT Excluding Unusual Items | -0.58 | -0.82 | -6.84 | -3.6 | -2.22 | -3.67 |
Merger & Restructuring Charges | - | - | - | - | - | -0.01 |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 0 |
Asset Writedown | -0.73 | -0.73 | -16.21 | - | - | -1.11 |
Other Unusual Items | - | - | - | - | - | 0.07 |
Pretax Income | -1.3 | -1.54 | -23.05 | -3.6 | -2.22 | -4.72 |
Net Income | -1.3 | -1.54 | -23.05 | -3.6 | -2.22 | -4.72 |
Net Income to Common | -1.3 | -1.54 | -23.05 | -3.6 | -2.22 | -4.72 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 963 | 960 | 912 | 640 | 38 | 35 |
Shares Outstanding (Diluted) | 963 | 960 | 912 | 640 | 38 | 35 |
Shares Change | 0.32% | 5.19% | 42.61% | 1588.74% | 7.42% | 1.01% |
EPS (Basic) | -0.00 | -0.00 | -0.03 | -0.01 | -0.06 | -0.13 |
EPS (Diluted) | -0.00 | -0.00 | -0.03 | -0.01 | -0.06 | -0.13 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 0.02 | 0.03 | -0.51 | -1.52 | -2.09 | -3.96 |
Free Cash Flow Per Share | - | - | -0.00 | -0.00 | -0.06 | -0.11 |
Gross Margin | 81.90% | 81.08% | 70.87% | 67.76% | 67.28% | 64.13% |
Operating Margin | -21.30% | -27.98% | -279.93% | -99.92% | -77.40% | -81.57% |
Profit Margin | -73.81% | -83.23% | -985.17% | -105.53% | -91.26% | -118.37% |
Free Cash Flow Margin | 1.07% | 1.61% | -21.95% | -44.41% | -85.88% | -99.39% |
EBITDA | -0.3 | -0.44 | -4.33 | -3.4 | -1.88 | -3.25 |
EBITDA Margin | -17.02% | -23.94% | -185.10% | -99.78% | -77.20% | -81.55% |
D&A For EBITDA | 0.08 | 0.08 | 2.22 | 0 | 0 | 0 |
EBIT | -0.38 | -0.52 | -6.55 | -3.41 | -1.89 | -3.25 |
EBIT Margin | -21.30% | -27.98% | -279.93% | -99.92% | -77.40% | -81.56% |
Revenue as Reported | 1.85 | 1.85 | 2.34 | 3.41 | - | - |
Advertising Expenses | - | 0.08 | 0.07 | - | - | - |